Frontlight ResearchEarly access
CompletedPhase 4
A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults
Key facts
- Who runs it
- Tor Biering-Sørensen
- Where
- Denmark2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 332,438 people enrolled
- Started
- 22 Sept 2022
- Ended
- 31 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- High-Dose Quadrivalent Influenza Vaccine
- Standard-Dose Quadrivalent Influenza Vaccine
- Record updated
- 12 September 2025
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Age 65 years and above (this inclusion criterion will be modified according to the Danish government's official recommendations for the 2022/2023 and 2023/2024 influenza seasons)
- Informed consent form has been signed and dated
Who cannot take part
- There are no specific exclusion criteria for this study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this pragmatic randomized trial is to evaluate the relative vaccine effectiveness of high-dose quadrivalent influenza vaccine (QIV-HD) vs. standard-dose quadrivalent influenza vaccine (QIV-SD) in older adults. Participants will be randomized 1:1 to either QIV-HD or QIV-SD.
The 2 groups in the trial
- High-Dose Quadrivalent Influenza VaccineTreatment being tested
QIV-HD single injection at Day 0
- Standard-Dose Quadrivalent Influenza VaccineExisting treatment, for comparison
QIV-SD single injection at Day 0
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Publications
- High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes: A Secondary Analysis of the DANFLU-2 Randomized Clinical Trial.JAMA internal medicine, 2026
- High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial.JAMA cardiology, 2025
- High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.The New England journal of medicine, 2025
- High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial.Circulation. Heart failure, 2025
- Patient-reported outcomes and home-based self-swabs for influenza-like illness events - lessons learned from the 2023/2024 DANFLU-2 Homeswab PRO substudy.Journal of patient-reported outcomes, 2025
- A pragmatic individually randomized trial to evaluate the effectiveness of high-dose vs standard-dose influenza vaccine in older adults: Rationale and design of the DANFLU-2 trial.American heart journal, 2026
- Record updated
- 12 September 2025